Advances and Controversies in Prostate Cancer

Urologic Clinics of North America
Volume 37, Issue 1, Pages 1-148 (February 2010)
Advances and Controversies in Prostate Cancer
Edited by William K. Oh, Jim C. Hu
in this issue of Urologic Clinics of North America, our outstanding contributors—all leaders in the field—review landmark studies that have shown that 5-alpha reductase inhibitors indeed are effective in the chemoprevention of prostate cancer. They also review other phase III studies that have raised questions about how aggressively we should screen the general population with prostate-specific antigen tests. Once prostate cancer is diagnosed, newer novel imaging techniques are allowing for better staging and—with some controversy—the possibility of guided and potentially focal therapeutics with cryotherapy and high-intensity focused ultrasound. Moreover, disruptive technologies, such as robotic-assisted laparoscopic surgery and the Internet have toppled traditional word-of-mouth referral patterns, making patients themselves drivers of early adoption of new technology. Moreover, for men opting for surgery, the appropriateness and extent of pelvic lymph node dissection remain unclear. The field of radiation therapy has also rapidly changed, and continued evidence for its efficacy is being evaluated both as primary and adjuvant therapy.

New data on systemic therapies are reviewed, including those given at the time of diagnosis and at the time of relapse, such as hormones and chemotherapy. A new immunotherapy treatment for prostate cancer will likely be commercially available in 2010. Indeed, perhaps the future of prostate cancer can be seen in new advances in the role of biomarkers and novel therapeutics, as molecular medicine begins to demonstrate promise in prostate cancer patients
http://rapidshare.com/files/380416173/feb_2010.rar